The global incidence of bullous pemphigoid: a systematic review and meta-analysis
- PMID: 34480482
- DOI: 10.1111/bjd.20743
The global incidence of bullous pemphigoid: a systematic review and meta-analysis
Abstract
Background: Bullous pemphigoid (BP) is an autoimmune blistering disorder that mainly affects older people. Although the disease is associated with considerable morbidity and mortality, the burden of disease worldwide is unclear.
Objectives: The study aim is to pool the global incidence of BP and determine whether this varies according to geographic area, age group, setting and study quality.
Methods: Ovid MEDLINE, Ovid Embase and grey literature were systematically searched on 7 April 2020. Two reviewers independently screened, extracted data and appraised each study's quality using the Joanna Briggs Institute critical appraisal tool. Two domains, indicative of selection and survey bias, were used to identify high-quality studies. The cumulative incidence was standardized to 1 year and pooled in a random-effects meta-analysis. Subgroup and sensitivity analyses were conducted.
Results: Twenty-seven studies were identified, of which 23 provided cumulative incidence and four provided incidence rates. The cumulative incidence of BP was 8·2 [95% confidence interval (CI) 4·8-13.7] per million people whereas the incidence rate was 34·2 (95% CI 19·2-60·7) per million person-years. Of the continents that contributed more than one study, the cumulative incidence was 10·3 (95% CI 5·8-18·2) and 5·6 (95% CI 3·5-9·0) per million people in Europe and Asia, respectively. The incidence was highest in studies including adults only (n = 2), in population-based studies (n = 9) and in more recent years. The cumulative incidence was higher (13·3 per million people, 95% CI 6·0-29·5) when restricting the analysis to higher-quality studies (n = 11). High heterogeneity (I2 > 82%) was observed across all pooled estimates.
Conclusions: The incidence of BP varies globally, is generally low but appears to be increasing over time. The burden of disease is likely to be underestimated.
© 2021 British Association of Dermatologists.
Comment in
-
Unfolding the worldwide incidence of bullous pemphigoid: what are we missing?Br J Dermatol. 2022 Mar;186(3):386-387. doi: 10.1111/bjd.20838. Epub 2021 Nov 22. Br J Dermatol. 2022. PMID: 34806169 No abstract available.
References
-
- Persson M, Harman K, Vinogradova Y et al. Incidence, prevalence and mortality of bullous pemphigoid in England 1998-2017: a population-based cohort study. Br J Dermatol 2021; 184:68-77.
-
- Silverii GA, Dicembrini I, Nreu B et al. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials. Endocrine 2020; 69:504-7.
-
- Liu S-D, Chen W-T, Chi C-C. Association between medication use and bullous pemphigoid: a systematic review and meta-analysis. JAMA Dermatol 2020; 156:891-900.
-
- Yang W, Cai X, Zhang S et al. Dipeptidyl peptidase-4 inhibitor treatment and the risk of bullous pemphigoid and skin-related adverse events: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev 2021; 37:e3391.
-
- Lai Y, Yew Y, Lambert W. Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2016; 30:2007-15.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous